The strong association between CXCL9/10 and effector T cell signatures observed in our NSCLC TCGA analysis as well as other studies suggests that the positive predictive value of CXCL9 as a biomarker of response to ICB could be due to its direct correlation with effector T cell responses, which are the critical immune mediators of response to immunotherapy.19 The gene discussed is CXCL9; the disease is non-small cell lung carcinoma.